Regulatory Context: IND-Enabling
Development Stage: Biomarker Discovery → GLP Transition
Regulatory Alignment: FDA (21 CFR 312) / EMA (ICH M3(R2), S7A, S7B, S9 where applicable)
SECTION 1 — OVERALL PRECLINICAL OBJECTIVES
Primary Objectives:
- Confirm multi-scale mechanistic plausibility (ECM–Mitochondrial–Neuroendocrine axes)
- Establish dose-response relationships
- Define NOAEL and MTD
- Validate translational biomarkers
- Assess safety pharmacology profile
Secondary Objectives:
- Confirm adaptive mitochondrial targeting behavior
- Quantify ECM remodeling normalization
- Evaluate neuroendocrine synchronization effects
SECTION 2 — PROGRAM STRUCTURE OVERVIEW
Phase A — In Vitro Mechanistic Validation
Phase B — In Vivo Pharmacology (Rodent)
Phase C — PK/PD Characterization
Phase D — Dose-Range Finding Toxicology
Phase E — GLP Repeat-Dose Toxicology
PHASE A — IN VITRO MECHANISTIC STUDIES
A1. Mitochondrial Bioenergetics Assay
Model Systems:
- Human primary fibroblasts
- SH-SY5Y neuronal cells
- HepG2 hepatocytes
Endpoints:
- Oxygen consumption rate (OCR)
- ATP production
- NAD+/NADH ratio
- ROS generation
- Mitochondrial membrane potential (Δψm)
Design:
- Concentration gradient (0.01 µM – 10 µM)
- Baseline vs oxidative stress challenge
- Triplicate experiments
Success Criteria:
- ≥20% stabilization of NAD+/NADH under stress
- No excessive ROS elevation
A2. ECM Remodeling Assay
Model:
- Human dermal fibroblast culture
Endpoints:
- MMP-2 / MMP-9 activity (zymography)
- Collagen I/III ratio
- Hyaluronic acid turnover
- TIMP expression
Success Criteria:
- ≥20% reduction in stress-induced MMP-9 elevation
- No collagen over-crosslink rigidity
A3. Neuroendocrine Signaling Assay
Model:
- Hypothalamic neuronal cell line
Endpoints:
- CRH expression
- Cortisol pathway surrogate markers
- NF-κB activation
Success Criteria:
- Reduced stress-induced NF-κB activation
- No baseline suppression beyond physiological range
PHASE B — IN VIVO PHARMACOLOGY (RODENT)
Species: Sprague-Dawley Rat
Group Size: n = 10 per group
Groups:
- Vehicle control
- Low dose
- Mid dose
- High dose
Duration: 28 days
B1. Primary Endpoints:
- Plasma NAD+/NADH
- Plasma MMP-9
- HRV measurement
- Corticosterone variability
B2. Secondary Endpoints:
- Collagen histology (skin & fascia)
- Mitochondrial density (TEM analysis)
- Behavioral stress response testing
Success Criteria:
- ≥25% improvement in NAD+/NADH stability
- ≥20% MMP-9 reduction
- Improved HRV coherence
- No adverse behavioral signal
PHASE C — PHARMACOKINETICS / BIODISTRIBUTION
Species:
- Rat (primary)
- Dog (non-rodent confirmatory)
Endpoints:
- Tmax
- Cmax
- Half-life
- Tissue distribution (mitochondrial fraction vs cytosol)
- CNS penetration ratio
Special Study:
Mitochondrial Enrichment Assay
- Isolate mitochondria from heart, liver, brain
- Measure compound concentration
Success Criteria:
- Mitochondrial concentration ≥2x cytosolic concentration
- Predictable clearance profile
PHASE D — DOSE RANGE FINDING (DRF)
Species:
- Rat + Dog
Duration:
- 14 days
Dose Escalation:
Low → Supra-therapeutic
Endpoints:
- Clinical signs
- Body weight
- Hematology
- Clinical chemistry
- Mineral accumulation (Zn, Cu)
Determine:
- MTD
- Preliminary NOAEL
PHASE E — GLP REPEAT-DOSE TOXICOLOGY
E1. 28-Day GLP Study (Rodent)
Groups:
- Control
- Low
- Mid
- High
Endpoints:
- Full clinical chemistry
- ECG
- Hormone panels
- Histopathology (heart, liver, kidney, brain, fascia)
- Mineral deposition analysis
E2. 90-Day GLP Study (Non-Rodent)
Endpoints:
- Organ weight
- Histopathology
- Neurobehavioral screening
- HPA-axis assessment
Define:
- Definitive NOAEL
- Safety Margin
- Target organ toxicity
SECTION 3 — BIOMARKER VALIDATION PACKAGE
Primary Translational Biomarkers:
- NAD+/NADH ratio
- MMP-9
- HRV coherence
- Cortisol rhythm
Validation Plan:
- Establish baseline variance
- Determine dose-response relationship
- Confirm reversibility post-treatment
SECTION 4 — STATISTICAL PLAN
Power Calculation:
α = 0.05
Power ≥ 80%
Analysis:
- ANOVA for multi-group comparisons
- Post hoc Tukey testing
- Repeated-measures ANOVA for longitudinal biomarkers
- PK modeling using non-compartmental analysis
SECTION 5 — RISK MITIGATION STRATEGY
Monitor:
- Excess AMPK activation
- Excessive mineral accumulation
- Cortisol suppression
- QT interval
Stopping Criteria:
- >15% body weight loss
- Severe behavioral abnormality
- 3x ALT elevation
- Significant ECG abnormality
SECTION 6 — GO / NO-GO DECISION MATRIX
Advance to IND if:
- NOAEL identified with ≥10x safety margin
- Biomarker improvements statistically significant
- No major organ toxicity
- PK profile predictable
Reformulate if:
- Mineral accumulation exceeds safe thresholds
- Chronic cortisol flattening observed
- Unacceptable cardiac findings
SECTION 7 — TIMELINE
In Vitro Studies: 4–6 months
In Vivo Pharmacology: 6 months
DRF Studies: 3 months
GLP Toxicology: 9–12 months
Total Estimated Preclinical Duration: 18–24 months
PRECLINICAL PROTOCOL STATUS: IND-ENABLING READY
If desired:
A. Generate Detailed GLP Study Protocol Template (Operational Level)
B. Generate Phase I First-in-Human Study Design
C. Generate CMC Development Plan
D. Generate Toxicology Statistical Analysis Plan (SAP)
E. Generate Regulatory Pre-IND Briefing Package
Respond with the letter only.